Nitpicking points from the overall report is silly which is what vacuum did. Revenue for product was in guidance with CEO commentary.
Yearly revenue increased substantially on last year as example. Also, not a full flu season run with Febridx in the US and revenue in line with previous years revenue for other regions also.
Revenue fluctuations will occur. Won’t always be consistently up each quarter fmd.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-41
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LDX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.001(2.33%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.3¢ | 3.9¢ | $100.6K | 2.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 623990 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 298309 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| LDX (ASX) Chart |